ArticleJournal of virology2008
Transformation by bovine papillomavirus type 1 E6 requires paxillin.
Article in Journal of virology, 2008. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 14 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
14 citing papers in PubMed, 24 citations in OpenAlex.
- Comparative structural studies on Bovine papillomavirus E6 oncoproteins: Novel insights into viral infection and cell transformation from homology modeling and molecular dynamics simulations.Genetics and molecular biology · 2024Article
- Human papillomavirus type 16 E6 induces cell competition.PLoS pathogens · 2022Article
- Manipulation of Focal Adhesion Signaling by Pathogenic Microbes.International journal of molecular sciences · 2021Review
- Multiple regions of E6AP (UBE3A) contribute to interaction with papillomavirus E6 proteins and the activation of ubiquitin ligase activity.PLoS pathogens · 2020Article
- Integrated mRNA and miRNA profiling in NIH/3T3 cells in response to bovine papillomavirusPeerJ · 2019Article
- Association of papillomavirus E6 proteins with either MAML1 or E6AP clusters E6 proteins by structure, function, and evolutionary relatedness.PLoS pathogens · 2017Article
- Papillomavirus E6 Oncoproteins Take Common Structural Approaches to Solve Different Biological Problems.PLoS pathogens · 2015Review
- Mutagenic Potential ofBos taurus Papillomavirus Type 1 E6 Recombinant Protein: First Description.BioMed research international · 2015Article
- Interactions between E6, FAK, and GIT1 at paxillin LD4 are necessary for transformation by bovine papillomavirus 1 E6.Journal of virology · 2014Article
- Papillomavirus E6 oncoproteins.Virology · 2013Review
- Structural basis for hijacking of cellular LxxLL motifs by papillomavirus E6 oncoproteins.Science (New York, N.Y.) · 2013Article
- Bovine papillomavirus clastogenic effect analyzed in comet assay.BioMed research international · 2013Article
- Cutaneous papillomavirus E6 oncoproteins associate with MAML1 to repress transactivation and NOTCH signaling.Oncogene · 2012Article
- Paxillin enables attachment-independent tyrosine phosphorylation of focal adhesion kinase and transformation by RAS.The Journal of biological chemistry · 2011Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors at 1 institution in 1 country.
Funding
Abstract
Papillomavirus E6 proteins are adapters that change the function of cellular regulatory proteins. The bovine papillomavirus type 1 E6 (BE6) binds to LXXLL peptide sequences termed LD motifs (consensus sequence LDXLLXXL) on the cellular protein paxillin that is a substrate of Src and focal adhesion kinases. Anchorage-independent transformation induced by BE6 required both paxillin and BE6-binding LD motifs on paxillin but was independent of the major tyrosine phosphorylation sites of paxillin. The essential role of paxillin in transformation by BE6 highlights the role of paxillin in the transduction of cellular signals that result in anchorage-independent cell proliferation.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.